MKS Instruments stock price target raised to $112 from $100 at Morgan Stanley

Morgan Stanley increased its price target for MKS Instruments (MKSI) to $112 from $100, reiterating an Overweight rating, citing improved fiscal year 2025 and 2026 revenue and EPS estimates based on updated semiconductor wafer fabrication equipment (WFE) forecasts. While the firm anticipates MKSI will outperform the broader WFE market, its EPS forecasts remain notably below consensus. This positive outlook from Morgan Stanley contrasts with mixed analyst sentiment, as TD Cowen maintains a Buy rating while Goldman Sachs initiated coverage with a Sell, reflecting divergent views on MKSI's growth trajectory within the semiconductor sector.

Analysis

MKS Instruments (MKSI) has received a positive revision from Morgan Stanley, which raised its price target to $112 from $100 and reiterated an Overweight rating. This upgrade is underpinned by increased fiscal year 2025 and 2026 estimates, with revenue forecasts now at $3.754 billion and $3.908 billion, respectively. The primary driver is an improved outlook for the wafer fabrication equipment (WFE) market, where Morgan Stanley projects MKSI's semiconductor segment growth of 14% in 2025 and 6% in 2026 to significantly outpace the broader WFE market. However, this optimism is tempered, as the firm's EPS forecasts remain 4% below consensus for FY25 and 8% below for FY26. Furthermore, the raised target multiple of 15x still implies a 25% valuation discount to peers, wider than the 10% five-year average. This reflects a divided sentiment on the Street, with TD Cowen maintaining a Buy rating and a $120 target, while Goldman Sachs recently initiated coverage with a Sell rating, citing concerns over semiconductor growth prospects. Supporting the bull case, the stock is reportedly trading at a low P/E relative to near-term growth, evidenced by a PEG ratio of 0.27, and the company continues to demonstrate shareholder commitment with a $0.22 quarterly dividend.

Key Decisions for Investors

• Investors should consider the bull case for MKSI, which is supported by Morgan Stanley's raised estimates, expectations of outperformance against the WFE market, and an attractive PEG ratio of 0.27.
• It is critical to weigh the significant divergence in analyst ratings, particularly Goldman Sachs' Sell initiation, and acknowledge that Morgan Stanley's own EPS forecasts remain below consensus, indicating potential risk to achieving market expectations.
• Monitor the upcoming earnings on August 6 for validation of the company's growth trajectory and track whether the stock's 25% valuation discount to peers begins to converge toward its 10% historical average.